Live Science on MSN20h
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugsThe telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Verywell Health on MSN6h
Benadryl vs. Hydroxyzine: How Do They Compare?Medically reviewed by Alex Yampolsky, PharmD Hydroxyzine, whose brand names include Atarax and Vistaril, and Benadryl, the ...
GlobalData on MSN23h
Boehringer seeks approval of lung disease drug after second Phase III successBoehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...
Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...
While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback